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Summary
Background Depression is the single largest contributor to non-fatal health loss worldwide. Second-generation 
antidepressants are the first-line option for pharmacological management of depression. Optimising their use is 
crucial in reducing the burden of depression; however, debate about their dose dependency and their optimal target 
dose is ongoing. We have aimed to summarise the currently available best evidence to inform this clinical question.
Methods We did a systematic review and dose-response meta-analysis of double-blind, randomised controlled 
trials that examined fixed doses of five selective serotonin reuptake inhibitors (SSRIs; citalopram, escitalopram, 
fluoxetine, paroxetine, and sertraline), venlafaxine, or mirtazapine in the acute treatment of adults (aged 18 years 
or older) with major depression, identified from the Cochrane Central Register of Controlled Trials, CINAHL, 
Embase, LILACS, MEDLINE, PsycINFO, AMED, PSYNDEX, websites of drug licensing agencies and 
pharmaceutical companies, and trial registries. We imposed no language restrictions, and the search was updated 
until Jan 8, 2016. Doses of SSRIs were converted to fluoxetine equivalents. Trials of antidepressants for patients 
with depression and a serious concomitant physical illness were excluded. The main outcomes were efficacy 
(treatment response defined as 50% or greater reduction in depression severity), tolerability (dropouts due to 
adverse effects), and acceptability (dropouts for any reasons), all after a median of 8 weeks of treatment (range 
4–12 weeks). We used a random-effects, dose-response meta-analysis model with flexible splines for SSRIs, 
venlafaxine, and mirtazapine.
Findings 28 554 records were identified through our search (24 524 published and 4030 unpublished records). 
561 published and 121 unpublished full-text records were assessed for eligibility, and 77 studies were included 
(19 364 participants; mean age 42·5 years, SD 11·0; 7156 [60·9%] of 11 749 reported were women). For SSRIs 
(99 treatment groups), the dose-efficacy curve showed a gradual increase up to doses between 20 mg and 40 mg 
fluoxetine equivalents, and a flat to decreasing trend through the higher licensed doses up to 80 mg fluoxetine 
equivalents. Dropouts due to adverse effects increased steeply through the examined range. The relationship between 
the dose and dropouts for any reason indicated optimal acceptability for the SSRIs in the lower licensed range between 
20 mg and 40 mg fluoxetine equivalents. Venlafaxine (16 treatment groups) had an initially increasing dose-efficacy 
relationship up to around 75–150 mg, followed by a more modest increase, whereas for mirtazapine 
(11 treatment groups) efficacy increased up to a dose of about 30 mg and then decreased. Both venlafaxine and 
mirtazapine showed optimal acceptability in the lower range of their licensed dose. These results were robust to 
several sensitivity analyses.
Interpretation For the most commonly used second-generation antidepressants, the lower range of the licensed dose 
achieves the optimal balance between efficacy, tolerability, and acceptability in the acute treatment of major depression.
Funding Japan Society for the Promotion of Science, Swiss National Science Foundation, and National Institute for 
Health Research.
Copyright © 2019 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license.
Introduction
Depression is the leading cause of disability worldwide.1 
The number of people living with depression increased 
by around 18% between 2005 and 2015, and depression 
affects 322 million people, or about 4% of the world’s 
population.1 Pharmacotherapy and psychotherapy are the 
two mainstays of depression treatment. In particular, 
second-generation anti depressants, including selective 
serotonin reuptake inhibitors (SSRIs), are the first-line 
options in the pharmacological management of major 
depression.2
However, there is still uncertainty about the dose 
dependency and optimal target dose of second-generation 
agents. Current practice guidelines provide conflicting 
recommendations: the National Institute of Health and 
Care Excellence guideline in UK states that no dose 
dependency has been established within the therapeutic 
range of SSRIs,3 whereas the American Psychiatric 
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Association (APA) guideline recommends titration up to 
the maximum tolerated dose: “Initial doses should be 
incrementally raised as tolerated until a therapeutic dose 
is reached...doses of antidepressant medications should 
be maximized, side effects permitting.”4 Systematic and 
comprehensive reviews of the literature examining 
dose dependency of antidepressants should clarify 
the issue and inform the guideline recommendations. 
Unfortunately, the available reviews are few and their 
conclusions disagree.5–7 Moreover, they addressed mainly 
dose-efficacy relationships and gave little attention to 
the balance between efficacy, tolerability, and overall 
acceptability of treatment.
We therefore did a dose-response meta-analysis of fixed-
dose studies of commonly prescribed antidepressants for 
the treatment of adults with major depression,2 examining 
not only their efficacy, but also their tolerability and 
acceptability, to provide summative evidence to inform 
future guideline recommendations.
Methods
Search strategy and selection criteria
We included double-blind, randomised controlled trials 
(RCTs) comparing antidepressants among themselves or 
with placebo as oral monotherapy for the acute-phase 
treatment of adults (aged 18 years or older) of both sexes, 
with a primary diagnosis of major depressive disorder 
according to standard operationalised diagnostic criteria. 
Trials of antidepressants for patients with depression and 
a serious concomitant physical illness were excluded.9 
This study focused on the most frequently prescribed 
new-generation antidepressants in the UK according to 
Open Prescribing,10 namely five SSRIs (citalopram, 
escitalopram, fluoxetine, paroxetine, and sertraline), 
venlafaxine, and mirtazapine.
The dataset was based on our 2016 network meta-
analysis,9 which was based on searches of the Cochrane 
Central Register of Controlled Trials, CINAHL, Embase, 
LILACS, MEDLINE, MEDLINE In-Process, PsycINFO, 
AMED, the UK National Research Register, and 
PSYNDEX. We scrutinised reference lists of all relevant 
papers. We searched files of the national drug licensing 
agencies in six countries (USA, UK, Netherlands, 
Sweden, Japan, and Australia), the European Medicines 
Agency, and several trial registries for published, 
unpublished, and ongoing RCTs. We contacted all 
pharmaceutical companies marketing second-generation 
antidepressants and asked for supplemental unpublished 
information about their pre-marketing and post-
marketing trials. We contacted the National Institute for 
Health and Care Excellence (UK), the Institut für Qualität 
und Wirtschaftlichkeit im Gesundheitswesen (Germany), 
and other relevant organisations and individuals for 
additional information not already identified. We used 
broad search terms for depression (depress* or 
dysthymi* or adjustment disorder* or mood disorder* or 
affective disorder or affective symptoms), and generic 
and commercial names of all antidepressants under 
Research in context
Evidence before this study
Second-generation antidepressants, including selective 
serotonin reuptake inhibitors (SSRIs), are the mainstay in the 
pharmacological management of major depression; however, 
current practice guidelines provide conflicting 
recommendations as to their optimum target dose. 
The National Institute of Health and Care Excellence guideline 
in the UK states that no dose dependency has been established 
within the therapeutic range of SSRIs, whereas the American 
Psychiatric Association guideline recommends titration up to 
the maximum tolerated dose. We searched for reviews that 
analysed dose-response relationships for second-generation 
antidepressants in PubMed using the search terms “depressive 
disorder”, “antidepressive agents, second-generation”, and 
“dose-response relationship, drug”, and in the references of the 
identified studies, up to March 21, 2019. We identified 
three systematic reviews: one concluded 21–40 mg fluoxetine 
equivalents provided maximum efficacy, another found 
40–50 mg fluoxetine-equivalent dose category offered the 
greatest efficacy, and the third confirmed a linearly increasing 
dose-efficacy relationship from placebo, to low doses, to high 
doses of SSRIs. Only two studies examined dose dependency for 
adverse effects, and only one examined dose dependency for 
acceptability of treatment.
Added value of this study
The current study is based on the largest and most 
comprehensive dataset of double-blind, randomised controlled 
trials, published and unpublished, that examined fixed doses of 
SSRIs, venlafaxine, or mirtazapine in the acute treatment of 
adults with major depression. Efficacy was dose dependent up to 
20–40 mg fluoxetine equivalents for SSRIs, up to 75–150 mg for 
venlafaxine, and up to approximately 30 mg for mirtazapine. 
Above these limits, no further increase in efficacy for SSRIs or 
mirtazapine occurred, but there was a slight increase in efficacy 
for venlafaxine. There was clear dose dependency in dropouts 
due to adverse effects for all drugs. Consequently, the overall 
acceptability of treatments was optimal towards the lower end 
of the licensed range for SSRIs, venlafaxine, and mirtazapine. In 
this state-of-the art dose-response meta-analysis, dose was 
treated as a continuous variable, allowing greater resolution of 
change points and avoiding misleading categorisation of doses.
Implications of all the available evidence
For the majority of patients receiving SSRIs, venlafaxine, or 
mirtazapine, the lower range of their licensed dose will 
probably achieve the optimal balance between efficacy, 
tolerability, and acceptability. This information should inform 
treatment guidelines and clinical decision making in routine 
clinical practice.
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review. We imposed no language restriction and the 
search was updated until Jan 8, 2016.
The complete dataset from the above search is available 
at Mendeley. There was no indication of small study 
effects, including publication bias, in this dataset.2 The 
reporting of the study followed the PRISMA guidelines.8 
The protocol is available on the institutional websites of 
Kyoto University and University of Oxford.
To examine dose-dependency relationships, we 
included all trials that compared two or more fixed-dose 
treatment groups including placebo (ie, active drug with 
placebo, or two or more doses of an active drug with or 
without placebo) within a trial. We included treatment 
groups within and outside the licensed dose range 
according to international drug approval agencies.
We evaluated the risk of bias in generation of allocation 
sequence, allocation concealment, masking of study 
personnel and participants, masking of outcome assessor, 
attrition, and selective outcome reporting. Studies were 
classified as having low risk of bias if none of these 
domains was rated as high risk of bias and three or fewer 
were rated as unclear risk; moderate if one was rated as 
high risk of bias or none was rated as high risk of bias, 
but four or more were rated as unclear risk; and all other 
cases were assumed to have high risk of bias.9
At least two independent reviewers selected the studies, 
extracted data, and assessed risk of bias.
Outcomes
We included the following outcomes after 8 weeks of 
treatment (range 4–12 weeks): treatment response (50% 
or greater reduction on an observer-rated scale for 
depression), dropouts due to adverse effects (as an index 
of treatment tolerability), and all-cause dropouts 
(interpreted as an overall index of treatment acceptability). 
For treatment response, we prioritised the Hamilton 
Depression Rating Scale,11 then Montgomery-Åsberg 
Depression Rating Scale,12 and if neither was used, any 
other validated observer-rating scale.9 When this outcome 
was not reported, we calculated response using a 
validated imputation method.13 We set the number of 
patients who were randomly assigned as the denominator 
for all outcomes, assuming that patients lost to follow-up 
had dropped out without experiencing response or 
dropout due to adverse effects.
Comparability of dose across drugs
Dose equivalence can be defined and calculated via several 
methods.14 One method assumes the optimum doses 
found in double-blind, flexible-dose trials to be equivalent.15 
In the main analyses, we used the most recent and 
comprehensive review of dose equivalence of anti-
depressants based on this method.16 Previous studies on 
dose dependency of antidepressants used similar con-
version algorithms.5,7 Where no empirical data for dose 
conversion were available, we assumed the daily defined 
dose (ie, the average maintenance dose per day calculated 
from the dose recommendations in each drug’s product 
information according to WHO17) to be equivalent. 
Another method assumes the average prescribed doses in 
the real world for the indication to be roughly equivalent. 
For this purpose, we used the nationally representative 
Medical Expenditure Panel Survey in USA.18,19 The dose 
conversion algorithms are provided in table 1.
Data analysis
We first estimated the dose dependency for the three 
primary outcomes by synthesising studies of all SSRIs. 
In this analysis we converted doses to fluoxetine 
equivalents using Hayasaka and colleagues’16 method, 
supplemented by the daily defined dose method. We 
fitted a single-stage, random-effects meta-analysis of 
dose-outcome model20 using the dosresmeta package in 
R.21 The approach estimates the association between the 
dose and the logarithm of risk ratio (RR) for each 
outcome within and across studies in a single model. We 
used flexible restricted cubic splines with knots at 10 mg, 
20 mg, and 50 mg to have comparable numbers of 
studies in each quartile between placebo, knots, and the 
maximum dose.
We also did separate analyses for individual SSRIs, and 
for venlafaxine and mirtazapine.
We did the following sensitivity analyses to examine the 
robustness of the main findings: setting a different 
number of knots and at different doses; using the con-
version algorithm in the previous study by Jakubovski and 
colleagues,7 or the conversion algorithm based on average 
doses actually prescribed for major depression;18,19 limiting 
the included studies to those at low risk of bias; and taking 
remission as the outcome. Remission was as per the 
original studies, which typically defined it as scoring seven 
or less on the Hamilton Depression Rating Scale or ten or 
less on the Montgomery-Åsberg Depression Rating Scale.
The data and the analysis R code that generated the 
results and figures can be found online.
Role of the funding source
The funders had no role in the design and conduct of the 
study; collection, management, analysis, and interpretation 
Bollini et al 
(1999)5
Jakubovski 
et al (2016)7
Hayasaka 
et al (2015)16
Medical 
Expenditure 
Panel Survey 
(2009, 
2018)18,19
Defined daily 
dose (2006)17
Current 
study
Citalopram 30 33·3 ·· 25·2 20 20
Escitalopram ·· 16·7 9 12·3 10 9
Fluoxetine 20 20 20 31·0 20 20
Paroxetine 20 20 17 30·4 20 17
Sertraline 83 120 49·3 72·0 50 49·3
Venlafaxine 100 ·· 74·7 133·1 100 74·7
Mirtazapine ·· ·· 25·5 19·1 30 25·5
Table 1: Antidepressant dose equivalence (mg) according to previous studies
For the complete dataset see 
https://data.mendeley.com/
datasets/83rthbp8ys/2
For the study protocol see 
http://ebmh.med.kyoto-u.ac.jp/r-
sys.html, and https://www.psych.
ox.ac.uk/team/andrea-cipriani
For the data and analysis code 
see https://github.com/esm-
ispm-unibe-ch-REPRODUCIBLE/
Dose_of_antidepressants
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of the data; preparation, review, or approval of the 
manuscript; and decision to submit the manuscript for 
publication.
Results
We identified 24 524 published records through electronic 
search, manual search, or personal communication, 
and 4030 unpublished records through industry and 
regulatory agency websites, contact with authors, and 
trial registries. 561 published and 121 unpublished full-
text records were assessed for eligibility, and we included 
77 studies examining various fixed doses of the included 
drugs: 27 studies based on published articles only, 
21 studies based on unpublished records only, and 
29 based on both published and unpublished records 
(figure 1). The 77 studies included 201 treatment groups: 
placebo (75 treatment groups), citalopram (17 treatment 
groups), escitalopram (16 treatment groups), fluoxetine 
(27 treatment groups), mirtazapine (11 treatment groups), 
paroxetine (28 treatment groups), sertraline (11 treatment 
groups), and venlafaxine (16 treatment groups). The study 
year ranged between 1986 and 2013. The full references 
and the characteristics of the included studies are 
presented in the appendix.
The 77 studies included 19 364 participants (6881 were 
allocated to placebo and 12 483 to active drug). Their 
mean age was 42·5 years (SD 11·0), and 7156 (60·9%) of 
11 749 participants for whom gender was reported were 
women. The median length of trial was 8 weeks 
(IQR 6–8). Nine studies had five treatment groups, 
29 had four treatment groups, 30 had three treatment 
groups, and nine had two treatment groups. 40 (52%) 
were done in North America, 13 (17%) in Europe, and 
ten (13%) were cross-continental. 18 (23%) took place in 
secondary or tertiary care, four (5%) in primary care, 
six (78%) in both primary and secondary care, and 
48 (62%) studies did not specify their study settings. The 
results of the risk of bias assessment are provided in the 
appendix. Many domains were rated as unclear and 
the overall risk of bias was rated as low in 21 (27%) 
studies, moderate in 55 (71%), and high in one (1%).
The dose-outcome relationship for treatment response, 
dropout due to adverse effects, and dropout for any 
reason for all SSRIs after the dose equivalence conversion 
are presented in figure 2. The RR for efficacy gradually 
increased from 1·0 for placebo, to 1·24 (95% CI 
1·18–1·30) for 20 mg, 1·27 (1·19–1·36) for 40 mg, and 
then showed a flat to decreasing trend through the higher 
doses (ie, 41–80 mg). Above 50 mg only a few doses were 
examined, resulting in less precise estimates with wider 
CIs in the upper dose range. The association between the 
dose and the dropouts due to adverse effects was linear to 
exponential, increasing from 1·0 for placebo, to 
1·94 (95% CI 1·63–2·31) at 40 mg, and to 3·73 (2·42–5·76) 
at the upper limit of the licensed range (80 mg). The 
association between the dose and the dropouts for any 
reason, reflecting dropouts for lack of efficacy and low 
tolerability, indicates optimal acceptability in the lower 
range between 20 mg and 40 mg. The point estimates 
and their 95% CIs of RRs and risk differences (RDs) for 
response, dropouts due to adverse effects, and dropouts 
for any reason at 10–80 mg of fluoxetine equivalents of 
SSRIs are presented in table 2.
The relationships between the dose and the 
three outcomes for each SSRI separately are presented 
in the appendix. The dose-outcome curves and their 
95% CIs substantially overlapped, suggesting little 
heterogeneity among the SSRIs in their dose-outcome 
relationships.
The dose-outcome relationships for venlafaxine and 
mirtazapine are presented in figures 3 and 4, respectively. 
The efficacy of venlafaxine increased fairly steeply up to 
around 75–150 mg and more modestly with higher doses 
(ie, 151–375 mg), whereas the efficacy of mirtazapine 
increased up to a dose of 30 mg and then decreased. 
Dropouts due to adverse effects increased steeply with 
increasing doses for both drugs, resulting in a dose-
acceptability curve that was convex at the lower licensed 
range, which approximately corresponded with 20–40 mg 
of fluoxetine equivalents in both cases. However, studies 
for each individual drug were few, and the 95% CIs of the 
spline curves remained wide.
We examined various knots when drawing spline 
curves for the dose-outcome curves for SSRIs (appendix). 
All curves overlapped with our primary analyses. When 
we examined different dose-equivalence calculations 
among SSRIs or limited to low risk of bias studies 
Figure 1: Study selection
24 524 published records identified through 
 electronic search, manual search, or personal 
 communication
23 963 excluded
 307 duplicates
 23 656 based on title and 
  abstract
561 full-text articles assessed for eligibility
505 excluded
 4 unable to check eligibility
 18 duplicate publication
 483 not fulfilling eligibility
   criteria 
56 eligible studies identified
4030 unpublished records identified through industry
 and regulatory agency websites, contact with
 authors, and trial registries
3909 excluded
 256 duplicates
 3653 wrong study design or
 population
121 full-text studies assessed for eligibility
71 excluded
      35 no results available
      36 not fulfilling eligibility criteria
50 eligible studies identified
77 studies included
 21 unpublished records only
 29 both published and unpublished records
 27 published records only
See Online for appendix
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Figure 2: Dose-outcome relationships for selective serotonin reuptake inhibitors (99 treatment groups)
RR=risk ratio. Each tick on the x-axis represents the dose examined in a treatment group. The dotted lines represent 95% CIs.
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Fluoxetine-equivalent dose (mg)
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Fluoxetine-equivalent dose (mg)
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Response Dropouts due to adverse effects Dropouts for any reason
RR RD RR RD RR RD
SSRIs
10 mg 1·12 (1·09 to 1·15) 0·04 (0·03 to 0·05) 1·18 (1·09 to 1·28) 0·01 (0·00 to 0·01) 0·93 (0·89 to 0·97) –0·02 (–0·03 to –0·01)
20 mg 1·24 (1·18 to 1·30) 0·08 (0·06 to 0·10) 1·40 (1·20 to 1·62) 0·02 (0·01 to 0·03) 0·88 (0·81 to 0·95) –0·03 (–0·05 to –0·01)
30 mg 1·29 (1·21 to 1·36) 0·10 (0·07 to 0·13) 1·65 (1·39 to 1·96) 0·03 (0·02 to 0·04) 0·87 (0·79 to 0·96) –0·03 (–0·05 to –0·01)
40 mg 1·27 (1·19 to 1·36) 0·09 (0·06 to 0·12) 1·94 (1·63 to 2·31) 0·04 (0·02 to 0·05) 0·91 (0·82 to 1·02) –0·02 (–0·05 to 0·01)
60 mg 1·18 (1·06 to 1·32) 0·06 (0·01 to 0·10) 2·69 (2·06 to 3·52) 0·07 (0·04 to 0·10) 1·04 (0·90 to 1·21) 0·01 (–0·03 to 0·05)
80 mg 1·09 (0·91 to 1·30) 0·02 (–0·04 to 0·09) 3·73 (2·42 to 5·76) 0·10 (0·05 to 0·19) 1·20 (0·97 to 1·49) 0·05 (–0·01 to 0·12)
Venlafaxine
37·5 mg 1·15 (1·06 to 1·25) 0·05 (0·02 to 0·09) 1·53 (1·25 to 1·87) 0·02 (0·01 to 0·03) 0·91 (0·71 to 1·17) –0·02 (–0·07 to 0·04)
75 mg 1·31 (1·12 to 1·52) 0·11 (0·04 to 0·18) 2·24 (1·53 to 3·29) 0·05 (0·02 to 0·09) 0·85 (0·54 to 1·33) –0·04 (–0·12 to 0·08)
150 mg 1·47 (1·24 to 1·75) 0·16 (0·08 to 0·26) 3·08 (1·95 to 4·85) 0·08 (0·04 to 0·15) 0·92 (0·64 to 1·32) –0·02 (–0·09 to 0·08)
225 mg 1·53 (1·31 to 1·78) 0·19 (0·11 to 0·27) 3·21 (2·09 to 4·92) 0·09 (0·04 to 0·16) 1·14 (0·87 to 1·48) 0·04 (–0·03 to 0·12)
300 mg 1·58 (1·30 to 1·95) 0·20 (0·11 to 0·33) 3·31 (2·02 to 5·44) 0·09 (0·04 to 0·18) 1·42 (0·75 to 2·69) 0·11 (–0·06 to 0·42)
375 mg 1·64 (1·25 to 2·14) 0·22 (0·09 to 0·40) 3·42 (1·81 to 6·45) 0·10 (0·03 to 0·22) 1·77 (0·60 to 5·19) 0·19 (–0·10 to 1·05)
Mirtazapine
7·5 mg 1·08 (1·01 to 1·16) 0·03 (0·00 to 0·06) 1·23 (1·05 to 1·46) 0·01 (0·00 to 0·02) 0·99 (0·88 to 1·11) 0·00 (–0·03 to 0·03)
15 mg 1·17 (1·02 to 1·34) 0·06 (0·01 to 0·12) 1·52 (1·09 to 2·13) 0·02 (0·00 to 0·05) 0·98 (0·78 to 1·23) –0·01 (–0·06 to 0·06)
30 mg 1·28 (1·03 to 1·58) 0·10 (0·01 to 0·20) 2·17 (1·26 to 3·73) 0·05 (0·01 to 0·11) 0·99 (0·67 to 1·46) 0·00 (–0·08 to 0·12)
45 mg 1·16 (0·95 to 1·42) 0·06 (–0·02 to 0·15) 2·54 (1·54 to 4·21) 0·06 (0·02 to 0·13) 1·07 (0·69 to 1·64) 0·02 (–0·08 to 0·16)
60 mg 0·95 (0·65 to 1·38) –0·02 (–0·12 to 0·13) 2·66 (1·44 to 4·92) 0·07 (0·02 to 0·16) 1·20 (0·71 to 2·05) 0·05 (–0·07 to 0·26)
RDs for efficacy, tolerability and acceptability were calculated from RRs and the average observed event rates of 35%, 4%, and 25% for response, dropouts due to side effects, 
and all-cause dropouts, respectively, in the included studies.
Table 2: Relative risks (RRs) and risk differences (RDs) for efficacy, tolerability and acceptability at various doses of selective serotonin reuptake inhibitors 
(SSRIs), venlafaxine, and mirtazapine
Articles
6 www.thelancet.com/psychiatry   Published online June 6, 2019   http://dx.doi.org/10.1016/S2215-0366(19)30217-2
Figure 3: Dose-outcome relationships for venlafaxine (16 treatment groups)
RR=risk ratio. Each tick on the x-axis represents the dose examined in a treatment group. The dotted lines represent 95% CIs.
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Figure 4: Dose-outcome relationships for mirtazapine (11 treatment groups)
RR=risk ratio. Each tick on the x-axis represents the dose examined in a treatment group. The dotted lines represent 95% CIs.
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(appendix), all the results were similar to the primary 
results (figure 1). The dose-remission relationship 
showed the same tendencies as the dose-response for 
SSRIs, venlafaxine, and mirtazapine (appendix).
Discussion
We did a comprehensive dose-response meta-analysis of 
the most commonly prescribed antidepressants, based on 
the largest pool of antidepressant trials for major 
depression.2 For SSRIs, the probability of response 
increased up to doses between 20 mg and 40 mg of 
fluoxetine equivalents, with no further increase or even a 
slight decrease at higher doses within the licensed dose 
range up to 80 mg. Dropouts due to adverse effects showed 
a steep, linear to exponential, increase with increase in 
dose. Consequently, dropouts from all causes, including 
for lack of efficacy and for adverse effects, were lowest 
between 20 mg and 40 mg. Venlafaxine and mirtazapine 
showed slightly different dose-efficacy relationships; 
however, all drugs showed optimal acceptability towards 
the lower end of their licensed dose range.
These results are in line with psychopharmacological 
investigations. Using PET scans, Meyer and colleagues22 
showed that approximately 80% serotonin transporter 
occupancy occurs at minimum therapeutic doses of 
citalopram, fluoxetine, paroxetine, sertraline, or 
venlafaxine, and that further increments in dose resulted 
in only small increases in transporter occupancy: a 
hyperbolic relationship typical of ligand-receptor binding.23 
Our data also suggest that increases in transporter 
occupancy above 80% do not result in greater treatment 
efficacy. Similarly, conventional antipsychotic drugs 
require dopamine D2 receptor occupancy of about 70% to 
achieve a therapeutic effect; greater D2 occupancy does not 
increase efficacy, but raises the incidence of side-effects.24 
Venlafaxine is a serotonin and noradrenaline reuptake 
inhibitor; however, functional noradrenaline reuptake 
blockade might become apparent only at higher doses 
(eg, 225 mg and 375 mg per day of venlafaxine).25 This 
dual action might be responsible for the observed increase 
in efficacy with higher doses for venlafaxine. Mirtazapine 
has more complex psychopharmacological properties, and 
the precise mechanisms underpinning its antidepressant 
action are less well understood. Mirtazapine is thought to 
increase noradrenaline and serotonin release through 
antagonism of central α2-adrenergic autoreceptors and 
heteroreceptors. It also exhibits antagonism to some 
serotonin (5-HT) receptor subtypes (5-HT2A, 5-HT2C, and 
5-HT3), while overall increasing tonic activation of post-
synaptic 5-HT1A receptors.26
Earlier reviews examining the clinical dose-efficacy 
relationship of antidepressants have produced variable 
results; some of this confusion might be due to arbitrary 
categorisation of doses and their inconsistent naming. 
Based on 33 studies of new-generation and older-
generation antidepressants (n=5844), Bollini and 
colleagues5 used four categories for dose (<20 mg, 
21–40 mg, 41–50 mg, and >50 mg of fluoxetine 
equivalents) and concluded that the response rate showed 
a gradual increase up to 21–40 mg, with no further 
increase for the two high-dose categories. The inclusion 
of older tricyclic antidepressants limits applicability of 
their review to modern practices. Hieronymus and 
colleagues6 analysed individual patient data from 11 trials 
of citalopram, paroxetine, and sertraline (n=2859) and 
found that “doses below or at the lower end of the 
recommended dose range were superior to placebo” and 
“inferior to higher doses”, suggesting a linearly increasing 
dose-efficacy relationship for SSRIs. Within their high-
dose categories corresponding with citalopram 40–60 mg, 
paroxetine 20–40 mg, or sertraline 100–200 mg, they 
found no indication of dose dependency. However, their 
category of low dose included subtherapeutic doses 
(citalopram 10 mg or paroxetine 10 mg) as well as 
therapeutic doses (citalopram 20 mg and sertraline 
50 mg), which might explain why the low-dose category 
did less well than the high-dose category in their analysis.
In 2016, Jakubovski and colleagues7 found a statistically 
significantly greater response for high doses in a meta-
regression analysis of 40 studies comparing SSRIs with 
placebo (n=10 039); an accompanying editorial27 
concluded, “there is a modest but clear dose-response 
effect for SSRIs.” However, when the findings were 
categorised into less than 20 mg, 20–39 mg, 40–50 mg, 
and more than 50 mg fluoxetine equivalents, the authors 
found the 40–50 mg dose category offered the greatest 
efficacy (ie, there was no general linear relationship 
between dose and efficacy over the whole dose range). 
Moreover, a majority of their included studies were 
flexible-dose studies and they took the maximum of the 
flexible range as the dose representing the treatment 
groups.
Our dose-dependency curves were based on models 
using splines, which treated dose as a continuous 
variable, and shed new light on the existing evidence. 
Our results for dose-efficacy relationships for SSRIs are 
largely in line with Bollini and colleagues.5 Hieronymus 
and colleagues’6 observation that there was a stepwise 
increase in efficacy from placebo, to low dose, to higher 
dose of SSRIs might be considered compatible with our 
finding of dose response up to 20–40 mg of fluoxetine 
equivalents; however, their categorisation of doses did 
not capture the change points identified in our analyses. 
Jakubovski and colleagues’7 conclusion that 40–50 mg of 
fluoxetine equivalents offered the greatest efficacy might 
be overstated if we take into account that most of their 
included studies used flexible-dose regimens and the 
prescribed doses could be significantly lower than 
40–50 mg.
Two studies examined the relationships between doses 
and side-effects. Bollini and colleagues5 found a monotonic 
increase in adverse event rates, from 20% to 50%, as the 
dose increased, from zero to more than 50 mg fluoxetine 
equivalents. Jakubovski and colleagues7 found a monotonic 
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dose relationship for dropouts due to side-effects, but an 
almost flat relationship for all-cause dropouts. These 
findings might be confounded by the inclusion of both 
fixed-dose and flexible-dose studies. By contrast, by 
focusing on fixed-dose studies and using flexible spline 
curves, we found a linear to exponential relationship 
between dose and dropouts due to side-effects, and a 
curvilinear relationship between dose and all-cause 
dropouts for SSRIs.
Our study is not without limitations. First, the findings 
mainly pertain to patients with major depression who 
were judged eligible for placebo-controlled trials. For 
patients who suffer from physical comorbidities or for 
older (ie, age ≥65 years) patients, the optimal dose might 
be lower than 20–40 mg fluoxetine equivalents. In this 
context, the positive dose-efficacy association through 
zero to 30 mg of fluoxetine equivalents is clinically 
relevant. Second, the fixed-dose regimen might be 
regarded as not reflecting clinical practice, especially 
when no or rapid titration scheme is used, and might 
overestimate withdrawal due to adverse effects. 
Tolerability might then confound efficacy because 
interventions with high dropouts are likely to show lower 
endpoint efficacy because the majority of patients leave 
the study early and therefore have less time to improve; 
however, strict examination of dose dependency is 
possible only with fixed-dose studies. Third, there is some 
uncertainty about how best to calculate dose equivalency 
among antidepressants. We used the most comprehensive 
empirically derived conversion algorithms,16 which were 
similar to the ones used in previous systematic reviews 
on this topic.5,7 We tested our results via sensitivity 
analyses that used alternative conversion algorithms and 
confirmed the primary results. Fourth, spline curves for 
individual drugs were based on a few studies, resulting in 
wide CIs. We therefore meta-analysed all SSRIs because 
they share a key therapeutic mechanism. The curves for 
individual SSRIs provided little evidence of heterogeneity. 
For venlafaxine and mirtazapine, the numbers of available 
trials were few and the resultant wide CIs, particularly 
regarding tolerability and acceptability, warn against 
overinterpreting the results. Fifth, we used dropouts for 
side-effects from the acute-phase treatment as an index of 
tolerability: these numbers do not necessarily reflect rare 
but severe adverse events, nor do they include long-term 
side-effects, including withdrawal symptoms. Lastly, the 
search date for the relevant studies could be considered 
old; however, an update search for eligible trials in 
PubMed on March 21, 2019 revealed only one additional 
eligible study with a small sample size (55 patients 
randomly assigned to paroxetine 10 mg and 49 to 
placebo),28 which would not change the results of our 
analysis with 19 364 patients.
Our study has a number of strengths. First, we used 
state-of-the art dose-response meta-analysis, and treated 
dose as a continuous variable, allowing greater resolution 
of change points and avoiding misleading categorisation 
of doses. Second, we examined dose dependency not 
only for efficacy but also for tolerability and acceptability. 
Third, our study is based on the largest and most 
comprehensive dataset of fixed-dose, double-blind, 
randomised controlled trials, published or unpublished, 
of second-generation antidepressants in the acute-phase 
treatment of major depression. The included numbers of 
studies and participants were two to eight times larger 
than the previous analyses. We analysed not only SSRIs, 
but also two widely prescribed non-SSRI antidepressants, 
venlafaxine and mirtazapine. Our findings will have 
clinical implications, especially for practitioners or 
countries where fluoxetine is routinely prescribed at 
doses of 40 mg or more.
In conclusion, our analyses showed dose dependency 
in efficacy up to around 20–40 mg fluoxetine equivalents, 
beyond which there is no further increase in efficacy for 
SSRIs or mirtazapine, but a possibly slight increase for 
venlafaxine; a clear dose dependency in dropouts due to 
adverse effects for all drugs through the examined dose 
range; and the overall acceptability of treatments appears 
to be optimal towards the lower end of the licensed 
range. We therefore conclude that for the majority of 
patients receiving an SSRI, venlafaxine, or mirtazapine 
for the acute-phase treatment of their major depressive 
episode, the lower range of the licensed dose will 
probably achieve the optimal balance between efficacy, 
tolerability, and acceptability. Clinical guidelines need to 
incorporate these findings.
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